incidence of factors influencing diabetes mellitus complications
DOI:
https://doi.org/10.35381/s.v.v6i1.1706Keywords:
Diabetes mellitus, diabetes mellitus experimental, hyperglycemia. (Source, DeCS).Abstract
Objective: To analyze the incidence of factors influencing complications of type II diabetes mellitus in the Hospital IESS Latacunga. Methods: Descriptive observational study. Results: 44% of people with diabetes also have hypertension, 18% mentioned high cholesterol, 8% low cholesterol, 28% high triglycerides and the remaining 2% said they had low triglycerides. Conclusion: The gender with the highest incidence of the disease is female at an age above 50 years; the majority of the parecientes apply insulin regularly and forgetfulness is considered frequent; in addition, people with diabetes tend to additionally suffer from hypertension and high triglycerides, and the excessive consumption of sugar can cause them to have frequent hospital visits.
Downloads
References
Rawshani A, Rawshani A, Franzén S, et al. Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes. N Engl J Med. 2017;376(15):1407-1418. doi:10.1056/NEJMoa1608664
Magliano DJ, Sacre JW, Harding JL, Gregg EW, Zimmet PZ, Shaw JE. Young-onset type 2 diabetes mellitus - implications for morbidity and mortality. Nat Rev Endocrinol. 2020;16(6):321-331. doi:10.1038/s41574-020-0334-z
Peer N, Balakrishna Y, Durao S. Screening for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2020;5(5):CD005266. doi:10.1002/14651858.CD005266.pub2
Baldeón ME, Felix C, Fornasini M, et al. Prevalence of metabolic syndrome and diabetes mellitus type-2 and their association with intake of dairy and legume in Andean communities of Ecuador. PLoS One. 2021;16(7):e0254812. doi:10.1371/journal.pone.0254812
Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018;14(2):88-98. doi:10.1038/nrendo.2017.151
Kautzky-Willer A, Harreiter J, Pacini G. Sex and Gender Differences in Risk, Pathophysiology and Complications of Type 2 Diabetes Mellitus. Endocr Rev. 2016;37(3):278-316. doi:10.1210/er.2015-1137
Kato ET, Silverman MG, Mosenzon O, et al. Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. Circulation. 2019;139(22):2528-2536. doi:10.1161/CIRCULATIONAHA.119.040130
Rachdaoui N. Insulin: The Friend and the Foe in the Development of Type 2 Diabetes Mellitus. Int J Mol Sci. 2020;21(5):1770. Published 2020 Mar 5. doi:10.3390/ijms21051770
Swinnen SG, Simon AC, Holleman F, Hoekstra JB, Devries JH. Insulin detemir versus insulin glargine for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2011;2011(7):CD006383. Published 2011 Jul 6. doi:10.1002/14651858.CD006383.pub2
Ceriello A, deValk HW, Guerci B, et al. The burden of type 2 diabetes in Europe: Current and future aspects of insulin treatment from patient and healthcare spending perspectives. Diabetes Res Clin Pract. 2020;161:108053. doi:10.1016/j.diabres.2020.108053
Maggio CA, Pi-Sunyer FX. Obesity and type 2 diabetes. Endocrinol Metab Clin North Am. 2003;32(4):805-viii. doi:10.1016/s0889-8529(03)00071-9
Pulgaron ER, Delamater AM. Obesity and type 2 diabetes in children: epidemiology and treatment. Curr Diab Rep. 2014;14(8):508. doi:10.1007/s11892-014-0508-y
Malone JI, Hansen BC. Does obesity cause type 2 diabetes mellitus (T2DM)? Or is it the opposite?. Pediatr Diabetes. 2019;20(1):5-9. doi:10.1111/pedi.12787
Sunil B, Ashraf AP. Dyslipidemia in Pediatric Type 2 Diabetes Mellitus. Curr Diab Rep. 2020;20(10):53. Published 2020 Sep 9. doi:10.1007/s11892-020-01336-6
Su WY, Chen SC, Huang YT, et al. Comparison of the Effects of Fasting Glucose, Hemoglobin A1c, and Triglyceride-Glucose Index on Cardiovascular Events in Type 2 Diabetes Mellitus. Nutrients. 2019;11(11):2838. Published 2019 Nov 19. doi:10.3390/nu11112838
Published
How to Cite
Issue
Section
License
CC BY-NC-SA : Esta licencia permite a los reutilizadores distribuir, remezclar, adaptar y construir sobre el material en cualquier medio o formato solo con fines no comerciales, y solo siempre y cuando se dé la atribución al creador. Si remezcla, adapta o construye sobre el material, debe licenciar el material modificado bajo términos idénticos.
OAI-PMH: https://fundacionkoinonia.com.ve/ojs/index.php/saludyvida/oai.
